WX0005

WX0005 is an investigational small molecule anti-epileptic drug (AED) developed by the Harbin Pharmaceutical Group Technical Center. It is classified as a Category 1 innovative drug in China, indicating it is a new chemical entity. The drug is primarily being developed for the treatment of epilepsy, a neurological disorder characterized by recurrent seizures. WX0005 functions as a voltage-gated sodium channel blocker; by binding to these channels, it stabilizes the neuronal membrane and prevents the high-frequency repetitive firing of neurons that leads to seizure activity. This mechanism is intended to provide a more stable and effective therapeutic profile compared to existing treatments. As of recent reports, WX0005 has progressed into clinical trials in China to evaluate its safety, pharmacokinetics, and preliminary efficacy in human subjects.